Precision BioSciences Reports Q3 2026 Results, $108 Million Cash Balance

What happened

Precision BioSciences reported a third-quarter 2026 net loss of $7.6 million, compared with a $21.8 million loss a year earlier, and ended September with $108.0 million in cash, cash equivalents and restricted cash. Revenue was zero for the quarter.

Confirmed

Global impact / market context

With no revenue, the company relies on its $108.0 million cash balance to fund research and operating costs. Management expects that cash to last through 2028, so investors can watch whether spending stays within that plan or forces new fundraising, which could dilute existing shareholders.

Analyst inference

The smaller net loss mainly reflects a non-cash gain from warrant liability changes, which means an accounting adjustment rather than cash saved from operations. Operating loss was roughly flat at $20.4 million, so the underlying cash burn remains the key measure for a clinical-stage biotech company.

Analyst inference

What to watch

1. Cash, cash equivalents and restricted cash fell to $108.0 million at September 30, 2026, from $137.2 million at December 31, 2025, showing the pace of cash use. Confirmed
2. The company expects its cash runway to extend through 2028; watch whether future quarterly reports keep that guidance or shorten it as trial costs rise with enrollment. Proposed
3. PBGENE-HBV enrollment and cohort expansion in the ELIMINATE-B trial raise research costs and may require added capital spending, which could pressure the cash balance before the stated runway ends. Analyst inference

Evidence

• Original source link unavailable